New drug combo aims to fight breast cancer in the brain
NCT ID NCT07166367
Summary
This study tested whether adding a new drug called ASLAN001 to an existing chemotherapy (capecitabine) could help control breast cancer that had spread to the brain and was getting worse despite prior radiation. It was for patients with a specific type of breast cancer called HER2-positive. The goal was to see if this combination could shrink the brain tumors and delay their progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Centre Singapore
Singapore, 169610, Singapore
Conditions
Explore the condition pages connected to this study.